81 results
6-K
EX-99.5
MOR
Morphosys AG
12 Apr 24
Current report (foreign)
10:54am
AG as follows regarding the goals pursued by the acquisi�on of vo�ng rights and the sources of funds: The investment by Kynam Capital Management, LP
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
Jahresbruttofixgehalts (Cap).
(2) In addition, the Executive receives an annual bonus in the amount of 80% of the fixed yearly gross salary if the goals agreed … und die ESG-Ziele werden vom Aufsichtsrat jeweils für das bevorstehende Geschäftsjahr festgelegt.
Assessment base for the bonus are company goals
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
a single shareholder and operating without a public listing increases the MorphoSys Group’s and Novartis’s ability to achieve the goals of the Proposed … goals, objectives and targets over the applicable periods. As a result, there can be no assurance that the Projections will be realized, and actual
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
place in the first half of 2024. As the closing process continues, I ask all of you to stay focused on our 2024 goals – progressing our important work
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
in the amount of 70% of the fixed yearly gross salary if the goals agreed upon are reached at one hundred percent. In case of shortfalls or overruns … die ESG-Ziele werden vom Aufsichtsrat jeweils für das bevorstehende Geschäftsjahr festgelegt.
Assessment base for the bonus are company goals defined
SC TO-T
EX-99
mtmkrm b5t0i5o58
11 Apr 24
Third party tender offer statement
6:01am
6-K
EX-99.1
d1h3yhy
20 Mar 24
Current report (foreign)
4:12pm
SC14D9C
EX-99.1
bs1azmz0rn5avb13r2dz
14 Mar 24
Written communication relating to third party tender offer
4:52pm
SC14D9C
EX-99.4
bkc6yvddhkzk
13 Mar 24
Written communication relating to third party tender offer
5:22pm
6-K
EX-99.1
7g0hrp053ch goqa5dih
13 Mar 24
Non-Financial Group Report 2023
4:12pm
6-K
EX-99.1
vc4j7bki828drmhe0jlo
13 Mar 24
Current report (foreign)
4:08pm
6-K
EX-99.3
5q01d5v2l7cj9bmhs
7 Feb 24
MorphoSys Enters into Business Combination Agreement to be
6:57am
SC14D9C
EX-99.10
ug1 9t0ke3dr9q04r
6 Feb 24
Written communication relating to third party tender offer
4:58pm
6-K
EX-99.2
ophtjxn
11 Dec 23
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
11:26am
6-K
EX-99.1
3yd v1bpw41925cfr
21 Nov 23
Topline Results Phase 3 MANIFEST-2 Study Pelabresib in First-Line Myelofibrosis November 2023 Gail, Living with Myelofibrosis since 2018
10:08am
F-3ASR
8jf e6175
16 Nov 23
Automatic shelf registration (foreign)
9:27am
6-K
EX-99.2
hsimfr1h5q
16 Nov 23
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
9:03am
6-K
EX-99.2
vdr03d36n9bv
10 Aug 23
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
9:22am
6-K
EX-99.2
i73r7j1q2t461urdi0xx
4 May 23
Current report (foreign)
9:20am